Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Linrodostat (BMS-986205)
NCT03374228Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linrodostat in solid tumor, sponsored by Bristol Myers Squibb. Primary endpoint: Absolute oral bioavailability (F) up to 15 days. Started Jan 2018; status: completed.
02
Drugs
linrodostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03374228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374228.